JMIR Publications

ABSTRACT

Background:

Coronary Artery Disease (CAD) is a leading cause of global morbidity and mortality. While CAD prevalence in the general population is well-documented, its occurrence among executive patients remains largely unexplored. Despite better access to care, this demographic faces unique challenges like demanding work schedules, chronic stress, frequent travel, and reduced control over lifestyle. Investigating whether these factors contribute to a different CAD prevalence within this subgroup is crucial.

Objective:

This protocol aims to design a study to determine the prevalence of CAD in executive patients and compare it to the established prevalence in the US general population with the overarching goal of improving screening and care of CAD among executive patients.

Methods:

This protocol proposes a retrospective review of medical records for patients with CAD seen at the Mayo Clinic's Executive Health Program from January 1, 2020, to December 31, 2023. The aim is to determine the prevalence of CAD in executive patients and compare it to reported rates in the US general population.

Conclusions:

In this protocol, we outline a research design and methodology to address a critical gap in understanding the prevalence of CAD among executive patients. This demographic is often overlooked despite their unique risk factors, such as high stress and lifestyle choices. By comparing CAD prevalence in this group to that of the general US population, we aim to identify specific cardiovascular risks faced by executives. Recognizing these risks will facilitate the development of targeted interventions tailored to their unique needs.